Navigation Links
Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
Date:2/22/2010

LAIYANG, China, Feb. 22 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for the second quarter of its fiscal year 2010 ended December 31, 2009.

    Second Quarter Highlights and Recent Events

    -- Revenue was $18.2 million, a decrease of 44.8% from the corresponding
       quarter ended December 31, 2008
    -- Gross profit was $13.5 million, compared to $25.8 million for the
       corresponding quarter ended December 31, 2008, and gross margin was
       74.3%, compared to 78.3% in the a year ago quarter ended December 31,
       2008
    -- Operating income was $7.1 million, down 37.4% from the corresponding
       quarter ended December 31, 2008
    -- Net income was $5.3 million, or $0.49 per basic share, compared $5.4
       million or $0.55 per basic share a year ago
    -- Excluding non-cash gains related to the change in fair value from
       derivative liabilities of $6.7 million and the amortization of debt
       discount and debt issuance costs related to convertible debentures of
       $5.8 million, non-GAAP adjusted net income was $4.4 million, or $0.29
       per fully diluted share for the three months ended December 31, 2009,
       compared to non-GAAP adjusted net income of $6.6 million, or $0.46 per
       fully diluted share, for the quarter ended December 31, 2008(*)
    -- Received renewal of Good Manufacture Practice ("GMP") certificate from
       the State Food and Drug Administration ("SFDA") for its tablets and
       granules
    -- In January 2010, Osteomyelitis treatment tablets were included in the
       2009 Edition of the National Basic Medical Insurance Directory

"Our second quarter sales volume was adversely impacted by the temporary production stoppage at our main facility related to the re-certification of our GMP certificate. In addition, we faced heightened competition associated with China's newly announced National Basic Medical Insurance plan," said Jiangbo's Chairman and CEO, Mr. Wubo Cao. "Our main facility has now returned to normal operations and we have reinforced our sales efforts. We expect sales volumes to improve in the second half of 2010. We continue our cost control efforts, which we expect to improve operational efficiency and drive organic growth, and we plan to leverage our strong cash position to bring in new drug opportunities."

Second Quarter of Fiscal Year 2010 Results

Total revenue for the three months ended December 31, 2009 was $18.2 million, a decrease of $14.8 million from $32.9 million for the three months ended December 31, 2008. The 44.8% decline was due to decreases in unit sales prices and sales volume. Unit sales prices for Clarithromycin Sustained-released tablets, Itopride Hydrochloride granules and Baobaole chewable tables decreased by an average of 26% following the restructuring of the Company's distribution and sales system in January 2009. Sales volumes declined due to renewal of the Company's GMP certificate, which resulted in a six-week production stoppage at the Company's main facility. Jiangbo received its GMP renewal certificate in December 2009, which is valid for a period of five years. Additionally, the Company's major products faced increasing competition from similar products included in China's newly announced National Basic Medical Insurance.

For the three months ended December 31, 2009, Clarithromycin Sustained-released tablets and Itopride Hydrochloride granules accounted for approximately 40.2% and 30.9% of total revenue, respectively. Baobaole chewable tables accounted for 16.9% of total revenue and were down 51.5% compared to the first quarter of fiscal 2010. Baobaole faced increased competition from Jianweixiaoshi tablet and zinc additives. Radix Isatidis dispersible tablets accounted for 11.9% of total revenue.

Gross profit in the second quarter of the fiscal year 2010 was $13.5 million, a decrease of 47.6% from $25.8 million for the prior year's corresponding period. Gross margin decreased to 74.3% from 78.3% for the prior year quarter, primarily due to the previously mentioned decrease in the unit prices.

Selling, general and administrative expenses were $5.3 million for the three months ended December 31, 2009, down 60.4% from $13.3 million in the three months ended December 31, 2008. Salaries, wages and related benefits decreased to $1.5 million from $9.2 million for the corresponding quarter of fiscal 2009, primarily due to a significant decrease in commissions paid to the Company's sales representatives in connection with the sales restructuring in January 2009. Advertising, marketing and promotion spending for the second quarter of fiscal 2010 was $2.2 million, a decrease of $0.4 million compared to one year ago.

Research and development expenses totaled $1.1 million for the three months ended December 31, 2009, consistent with the three months ended December 31, 2008. The Company is obligated to make monthly payment to the designated university/institute research and development projects pursuant to two cooperative research and development agreements which were signed in fiscal 2008.

Income from operations was $7.1 million, a 37.4% decrease from $11.4 million for the three months ended December 31, 2008.

Other income was $0.2 million compared to other expense of $3.2 million for the three months ended December 31, 2008. Other income was primarily due to non-cash gains related to the change in fair value from derivative liabilities of $6.7 million, which the Company did not record in the prior corresponding period, and the amortization of debt discount and debt issuance costs related to convertible debentures of $5.8 million versus $1.2 million in the prior year period.

Net income for the three months ended December 31, 2009 was $5.3 million, compared to $5.4 million in the year ago quarter. Basic earnings per share were $0.49, compared with $0.55 per basic share a year ago. Diluted earnings per share assumes the conversion of the Company's convertible notes and is calculated by adding interest expense to and deducting the loan issuance costs and unamortized debt discount from net income. As a result, the Company recorded a loss of $1.06 per diluted share, compared to a loss of $1.87 per diluted share in the same quarter last year.

Excluding non-cash gains related to the change in fair value from derivative liabilities of $6.7 million and the amortization of debt discount and debt issuance costs related to convertible debentures of $5.8 million, non-GAAP adjusted net income was $4.4 million, or $0.29 per fully diluted share for the three months ended December 31, 2009, compared to non-GAAP adjusted net income of $6.6 million, or $0.46 per fully diluted share, for the quarter ended December 31, 2008.

    (*) See the reconciliation table at the end of this press release for a
        reconciliation of net income and EPS to non-GAAP adjusted net income
        and EPS.

Six Month Results

Total revenue for the six month period ended December 31, 2009 was $42.6 million, down 29.7% from $60.5 million for the six month period ended December 31, 2008.

Gross profit totaled $31.6 million, down 33.5% from $47.6 million in the year ago period. Gross profit margin was 74.3% for the six month compared to 78.7% for the corresponding period in 2008. Operating income was $19.8 million, a 5.6% increase year-over-year from $18.8 million last year. Net income was $7.5 million, or $0.70 basic earnings per share, compared to $8.5 million, or $0.87 basic earnings per share, for the corresponding period in 2008. Diluted loss per share was $0.89 per share, compared to $1.61 diluted loss per share in the year ago period. Excluding non-cash gains related to the change in fair value from derivative liabilities of $1.9 million and the amortization of debt discount and debt issuance costs related to convertible debentures of $8.0 million, non-GAAP adjusted net income was $13.6 million, or $0.92 per fully diluted share for the three months ended December 31, 2009, compared to non-GAAP adjusted net income of $10.5 million, or $0.74 per fully diluted share, for the quarter ended December 31, 2008.

Financial Condition

As of December 31, 2009, the Company had $89.0 million in cash and an additional $14.5 million in restricted cash, as compared to $104.4 million and $7.3 million, respectively, at the end of fiscal 2009. The decline in cash was mainly attributable to the November 2009 purchase of land use rights for future factory expansion for $17.0 million and repayments for bank loans of $2.2 million. Working capital was $99.8 million, consistent with the level as of June 30, 2009. Shareholder's equity was $104.3 million, as compared to $126.1 million at the end of fiscal 2009. The decrease in shareholder's equity was the result of the reclassification of the Company's derivative instruments from the equity section to liability section of the balance sheet. The Company generated $3.2 million in cash flow from operating activities in the first half of fiscal 2010.

Business Outlook and Guidance

"Improving our operational efficiency, building our pipeline and strengthening our management team are expected to be our top priorities right now," said Mr. Cao. "We are already taking steps to address these challenges and look forward to providing updates on our progress."

Jiangbo's management has begun reviewing the existing marketing and sales system, including sales force compensation and incentive and effectiveness of our advertising activities. The Company is planning to take steps to reduce and eliminate operational inefficiencies and drive sales growth.

The Company recognizes the need to improve its product pipeline in order to ensure long term growth. In the past several months, the Company has been actively searching for new branded drug opportunities to license or acquire. Management expects revenues to improve in the second half of fiscal 2010. As such, the Company is maintaining its fiscal 2010 revenue guidance of $96 million to $98 million and operating income guidance of $42 million to $44 million.

Subsequent Events

On February 15, 2010, the Company entered into an agreement with one of the holders of its convertible notes, Pope Investments LLC ("Pope"), whereby Pope agreed to waive certain provisions set forth in the November 2007 and May 2008 securities purchase agreements for the Company's debentures and convertible notes, provided that the Company has made the November 2009 interest payments to the holders of the Company's November 2007 debentures and May 2008 notes on or prior to February 25, 2010. If the interest payments are not made by February 25, 2010 all rights and remedies of Pope defined in the 2007 and 2008 Securities Purchase Agreements shall remain in full force and effect as if this waiver had not been granted.

The Company also agreed that in the event that its common stock has not been listed on the NASDAQ Stock Market on or prior to April 15, 2010, it will pay to the holders of the 2007 Notes and the 2008 Notes an amount equal to the difference between the interest on such Notes previously paid for the period from June 1, 2009 to November 30, 2009.

Conference Call

Jiangbo Pharmaceuticals, Inc. management will host a conference call at 8:30 a.m. Eastern on Friday, February 26, 2010 to discuss financial results for the second quarter ended December 31, 2009 of its fiscal year 2010. The conference call will include Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO, of Jiangbo. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (877) 700-5838. International callers should dial +1 (706) 758 - 5465. The Conference ID for this call is 58049438.

If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Friday, February 26, 2010 at 9:30 a.m. Eastern Time. To access the replay, dial (800) 642-1687, international callers dial (706) 645-9291. Conference ID is 58049438.

Use of Non-GAAP Adjusted Financial Information

This press release includes certain financial information, non-GAAP adjusted net income and non-GAAP adjusted fully diluted earnings per share, which are not presented in accordance with GAAP. Non-GAAP adjusted net income was derived by taking net income and adjusting it with non-cash gains or losses related to the change in fair value from derivative liabilities and the amortization of debt discount and debt issuance costs related to convertible debentures. The Company's management believes that these non-GAAP adjusted measures provide investors with a better understanding of the Company's historical results from its core business operations. To supplement the Company's condensed consolidated financial statements presented on a non-GAAP adjusted basis, the Company has provided non-GAAP adjusted financial information, which is non-GAAP adjusted net income and non-GAAP adjusted earnings per share, excluding the impact of these items in this press release. The non-GAAP adjusted information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP adjusted financial information provided by the Company may also differ from non-GAAP adjusted information provided by other companies. A table at the end of this press release provides a reconciliation of the non-GAAP adjusted financial information to the nearest GAAP measure.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs, improve operational efficiency, in-license or acquire new drugs, make required interest payment and NASDAQ listing. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

                      -- Financial Statements Follow --



                JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES
         (FORMERLY KNOWN AS GENESIS PHARMACEUTICAL ENTERPRISES, INC.)
       CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
     FOR THE THREE MONTHS AND SIX MONTHS ENDED DECEMBER 31, 2009 AND 2008
                                 (UNAUDITED)

                           For the Three Months Ended For the Six Months Ended
                                  December 31,               December 31,
                               2009          2008         2009        2008
    REVENUES:
      Sales                $18,179,942   $32,944,809  $42,563,996 $60,265,493
      Sales - related
       parties                      --            --           --     243,909
         Total revenues     18,179,942    32,944,809   42,563,996  60,509,402

    COST OF SALES
      Cost of sales          4,667,049     7,138,166   10,927,448  12,851,210
      Cost of sales -
       related parties              --            --           --      54,493
          Total cost of
           sales             4,667,049     7,138,166   10,927,448  12,905,703

    GROSS PROFIT            13,512,893    25,806,643   31,636,548  47,603,699

    RESEARCH AND
     DEVELOPMENT EXPENSE     1,106,385     1,098,525    2,205,960   2,196,450

    SELLING, GENERAL
     AND ADMINISTRATIVE
     EXPENSES                5,259,213    13,282,421    9,601,019  26,634,396

    INCOME FROM
     OPERATIONS              7,147,295    11,425,697   19,829,569  18,772,853

    OTHER (INCOME) EXPENSE:
      Change in fair value
       of derivative
       liabilities          (6,687,085)           --   (1,865,992)         --
      Other income -
       related parties         (80,668)      (92,774)    (161,304)   (236,724)
      Non-operating
       (income) expense,
       net                     366,685       204,001      214,271   1,193,592
      Interest expense,
       net                   6,162,640     1,549,331    8,919,818   2,902,125
      Loss from
       discontinued
       operations               87,561     1,545,607      164,769   1,590,823
         Total other
          (income) expense,
          net                 (150,867)    3,206,165    7,271,562   5,449,816

    INCOME BEFORE PROVISION
     FOR INCOME TAXES        7,298,162     8,219,532   12,558,007  13,323,037

    PROVISION FOR INCOME
     TAXES                   1,970,021     2,820,346    5,078,191   4,790,367

    NET INCOME              $5,328,141    $5,399,186   $7,479,816  $8,532,670

    OTHER COMPREHENSIVE
     INCOME:
      Unrealized holding
       gain (loss)              32,827      (384,650)      56,371  (1,947,617)
      Foreign currency
       translation
       adjustment               44,704       248,823      196,884     579,464

    COMPREHENSIVE INCOME    $5,405,672    $5,263,359   $7,733,071  $7,164,517

    BASIC WEIGHTED
     AVERAGE NUMBER
     OF SHARES              10,983,405     9,771,883   10,744,648   9,770,615

    BASIC EARNINGS PER
     SHARE                       $0.49         $0.55        $0.70       $0.87

    DILUTED WEIGHTED
     AVERAGE NUMBER
     OF SHARES              15,065,301    14,148,317   14,829,605  14,173,463

    DILUTED EARNINGS
     (LOSS) PER SHARE           $(1.06)       $(1.87)      $(0.89)     $(1.61)



                JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES
         (FORMERLY KNOWN AS GENESIS PHARMACEUTICAL ENTERPRISES, INC.)
                         CONSOLIDATED BALANCE SHEETS
                  AS OF DECEMBER 31, 2009 AND JUNE 30, 2009

                                                  December 31,     June 30,
                                                      2009           2009
                                                  (Unaudited)
                     ASSETS
    CURRENT ASSETS:
      Cash and cash equivalents                    $88,971,243   $104,366,117
      Restricted cash                               14,545,305      7,325,000
      Investments                                       42,599        879,228
      Accounts receivable, net of allowance for
       doubtful accounts of $1,276,843 and
       $694,370 as of December 31, 2009 and
       June 30, 2009, respectively                  19,729,985     19,222,707
      Inventories                                    3,935,239      3,277,194
      Other receivables                                  4,447        167,012
      Other receivable - related parties               161,370             --
      Advances to suppliers                            472,939        236,496
      Financing costs - current                        632,637        680,303
        Total current assets                       128,495,764    136,154,057

    PLANT AND EQUIPMENT, net                        13,661,593     13,957,397

    OTHER ASSETS:
      Restricted investments                           129,306      1,033,463
      Financing costs, net                             131,278        556,365
      Intangible assets, net                        33,243,462     17,041,181
        Total other assets                          33,504,046     18,631,009

          Total assets                            $175,661,403   $168,742,463

      LIABILITIES AND SHAREHOLDERS' EQUITY

    CURRENT LIABILITIES:
      Accounts payable                              $2,875,667     $6,146,497
      Short term bank loans                                 --      2,197,500
      Notes payable                                 14,545,305      7,325,000
      Other payables                                 2,342,231      2,152,063
      Refundable security deposits due to
       distributors                                  4,107,600      4,102,000
      Other payables - related parties                 332,689        238,956
      Accrued liabilities                              368,578      1,356,898
      Liabilities assumed from reorganization          525,739      1,565,036
      Taxes payable                                  3,608,665     11,248,226
        Total current liabilities                   28,706,474     36,332,176

    OTHER LIABILITIES:
      Derivative liabilities                        33,996,855             --
      Convertible debt, net of discount
       $20,945,255 and $28,493,089 as of
       December 31, 2009 and June 30, 2009,
       respectively                                  8,694,745      6,346,911
        Total other liabilities                     42,691,600      6,346,911

          Total liabilities                         71,398,074     42,679,087

    COMMITMENTS AND CONTINGENCIES

    SHAREHOLDERS' EQUITY:
      Convertible preferred stock Series A
       ($0.001 par value; 0 shares issued and
       outstanding as of December 31, 2009 and
       June 30, 2009, respectively                          --             --
      Common stock ($0.001 par value,
       22,500,000 and 15,000,000 shares
       authorized, 11,169,546 and 10,435,099
       shares issued and outstanding as of
       December 31, 2009 and June 30, 2009,
       respectively)                                    11,170         10,435
      Additional paid-in capital                    23,805,104     48,397,794
      Capital contribution receivable                  (11,000)       (11,000)
      Retained earnings - unrestricted              70,427,320     67,888,667
      Statutory reserves                             3,253,878      3,253,878
      Accumulated other comprehensive income         6,776,857      6,523,602
        Total shareholders' equity                 104,263,329    126,063,376
          Total liabilities and shareholders'
           equity                                 $175,661,403   $168,742,463



                JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES
         (FORMERLY KNOWN AS GENESIS PHARMACEUTICAL ENTERPRISES, INC.)
                    CONSOLIDATED STATEMENTS OF CASH FLOWS
             FOR THE SIX MONTHS ENDED DECEMBER 31, 2009 AND 2008
                                 (Unaudited)

                                                     For the Six Months Ended
                                                            December 31,
                                                          2009        2008
    CASH FLOWS FROM OPERATING ACTIVITIES:
      Net income                                       $7,479,816  $8,532,670
      Loss from discontinued operations                   164,769   1,590,823
      Income from continuing operations                 7,644,585  10,123,493
      Adjustments to reconcile net income to
       net cash, net of acquisition, provided
       by operating activities:
         Depreciation                                     391,435     289,749
         Amortization of intangible assets                803,234     147,120
         Amortization of deferred debt issuance costs     472,753     340,151
         Amortization of debt discount                  7,547,834   1,646,235
         Loss from issuance of shares in lieu
          of interest                                     317,124          --
         Bad debt expense                                 581,287     111,237
         Realized loss (gain) on marketable
          securities                                      406,551    (115,128)
         Unrealized (gain) loss on marketable
          securities                                     (265,747)  1,459,656
         Other non-cash settlement                             --     (20,000)
         Change in fair value of derivative
          liabilities                                  (1,865,992)         --
         Stock-based compensation                         135,104      38,028
      Changes in operating assets and liabilities
         Accounts receivable                           (1,062,126) (1,764,421)
         Accounts receivable - related parties                 --     488,580
         Inventories                                     (653,303) (1,049,318)
         Other receivables                                161,727  (2,175,378)
         Other receivables - related parties             (161,304)   (236,724)
         Advances to suppliers and other assets          (235,033)  1,608,131
         Accounts payable                              (3,277,854)    569,601
         Other payables                                   187,153   1,815,563
         Other payables - related parties                  93,588      66,028
         Accrued liabilities                             (299,688)    153,587
         Liabilities assumed from reorganization          (79,150)   (903,600)
         Taxes payable                                 (7,651,766) 13,821,621
            Net cash provided by operating
             activities                                 3,190,415  26,414,211

    CASH FLOWS FROM INVESTING ACTIVITIES:
      Proceeds from sale of marketable securities         531,333     117,614
      Purchase of equipment and building improvements     (76,707)   (128,179)
      Purchase of land use right                      (16,975,633)         --
            Net cash used in investing activities     (16,521,007)    (10,565)

    CASH FLOWS FROM FINANCING ACTIVITIES:
      Change in restricted cash                        (7,207,356)  1,292,162
      Proceeds from bank loans                                 --   2,196,450
      Payments for bank loans                          (2,199,600) (2,782,170)
      Proceeds from notes payable                      14,539,356     704,328
      Principal payments on notes payable              (7,332,000)         --
         Net cash (used in) provided by financing
          activities                                   (2,199,600)  1,410,770

    EFFECTS OF EXCHANGE RATE CHANGE IN CASH               135,318     369,646

    (DECREASE) INCREASE IN CASH                       (15,394,874) 28,184,062

    CASH and CASH EQUIVALENTS, beginning              104,366,117  48,195,798

    CASH and CASH EQUIVALENTS, ending                 $88,971,243 $76,379,860

    SUPPLEMENTAL DISCLOSURES OF CASH FLOW
     INFORMATION:
      Cash paid for Interest                             $390,861  $1,110,572
      Cash paid for Income taxes                       $1,289,849    $128,329

    Non-cash investing and financing activities:
      Common stock issued for interest payment           $667,500         $--
      Common stock issued for convertible notes
       conversion, net of discount                     $5,200,000    $160,000
      Derivative liability reclassified to equity
       upon conversion                                 $4,049,887         $--
      Transfer of investments to settle liabilities
       assumed from reorganization                     $1,124,916         $--



                JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES
         (FORMERLY KNOWN AS GENESIS PHARMACEUTICAL ENTERPRISES, INC.)
            RECONCILIATION OF NON-GAAP NET INCOME AND DILUTED EPS

                             For Three Months              For Six Months
                             Ended December 31,          Ended December 31,
                             2009          2008          2009          2008

    Net Income            $5,328,141    $5,399,186    $7,479,816    $8,532,670
    Loss (gain) in fair
     value of derivative
     liabilities         $(6,687,085)          $--   $(1,865,992)          $--
    Amortization of
     debt discount
     and debt issuance
     costs related to
     convertible
     debentures           $5,751,934    $1,153,759    $8,020,587    $1,986,386

    Adjusted Net
     Income               $4,392,990    $6,552,945   $13,634,411   $10,519,056

    Basic Weighted
     Average Number
     of Shares            10,983,405     9,771,883    10,744,648     9,770,615

    Diluted Weighted
     Average Number
     of Shares**          15,065,301    14,148,318    14,829,605    14,173,463

    Adjusted Diluted
     Earnings per
     Share                     $0.29         $0.46         $0.92         $0.74


    ** Including outstanding options and warrants using treasury method of
       calculation plus the number of shares if converted from the convertible
       debt


    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-903-9378 x2
     Email: elsasung@jiangbo.com
     Web:   http://www.jiangbopharma.com

    CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Phone: +1-646-833-3417
     Email: lei.huang@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com

SOURCE Jiangbo Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.jiangbopharma.com

'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
2. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Noom, Inc., ... it will charge enterprise customers only when their members ... the health and wellness sector, which typically charges for ... - http://photos.prnewswire.com/prnh/20161207/446824LOGO ... the power of technology with the empathy of live ...
(Date:12/8/2016)... , Dec. 8, 2016 Augmedix, ... announced that it has closed a $23 million ... Ventures and OrbiMed. The company seeks to rehumanize ... physicians spend on mandated EHR documentation. The Augmedix ... service that frees doctors from 3 hours of ...
(Date:12/8/2016)... N.Y. , Dec. 8, 2016 Henry Schein, ... of health care products and services to office-based dental, animal ... 80 percent equity investment in Marrodent, one of ... of approximately $32 million. This transaction was announced on August ... customers in Poland since 2014, and ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift ... lines by smoothing and tightening the skin of the face to create more ... facial aging with very little downtime, Silhouette Instalift is a novel, minimally invasive ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning of ... an emergency medical call when he lost control of his patrol car. The vehicle ... his vehicle, he was transported to Atlanta Medical Center, where he later succumbed to ...
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is now ... to restore a more youthful appearance to the face. Dr. Peyman Ghasri and Dr. ... a variety of other treatments, to rejuvenate and renew the facial appearance. , ...
(Date:12/7/2016)... Ill. (PRWEB) , ... December 07, 2016 , ... Levels ... early-stage brain damage, according to a study appearing online in the journal Radiology. , ... is expected to increase significantly due to the rapidly aging population. Damage to both ...
Breaking Medicine News(10 mins):